Aetion pushes Series B to $82M as pandemic puts real-world evidence under the spotlight

Jason Mast

Editor

Former FDA chief Scott Gottlieb’s favorite real-world evidence platform is getting a new stream of cash, as it nears what will likely be the biggest …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Aetion pushes Series B to $82M as pandemic puts real-world evidence under the spotlight

Jason Mast

Editor

Sign up to read this article for free.

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

FDA approves subcutaneous version of Bristol Myers' Opdivo

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Ae­tion push­es Se­ries B to $82M as pan­dem­ic puts re­al-world ev­i­dence un­der the spot­light

Jason Mast

Editor

Sign up to read this article for free.

more like this

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Aetion pushes Series B to $82M as pandemic puts real-world evidence under the spotlight

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

FDA approves subcutaneous version of Bristol Myers' Opdivo

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma